TruTag Technologies, a provider of product identity solutions, has added mobile-phone authentication of solid oral-dosage form tablets to its product offerings.
On Sept. 5, 2018, TruTag Technologies, a provider of product identity solutions, announced the extension of its product identity platform to include mobile-phone authentication of solid oral-dosage form tablets.
The company manufactures microscopic, edible, optical barcodes, called TruTags, that can be applied directly on a product in ink or as part of the film coating process. The tags allow for instant and unequivocal product authentication for use in identifying supply-chain anomalies such as counterfeits, quality-control incidents, and unauthorized product diversion.
The tags are currently authenticated via a proprietary device that forms part of a secure, closed-loop product identity platform. The company has now extended its platform to allow for mobile-phone authentication. The solution is currently focused on tablet-form drug products but is planned to be extended to other solid oral-dosage form products such as capsules, the company reports.
“Traditional product security solutions that rely on authenticating packaging can be easily circumvented,” said Tim Learmonth, PhD, head of Advanced Development, in a company press release. “With TruTags we identify the product itself. Before now, the ability to offer instantaneous authentication of a tablet or capsule to the patient population has not existed. Our solution represents a significant step forward for supply-chain security.”
The benefits of mobile-phone authentication extend beyond supply-chain security. Providing clients with the tools to authenticate products offers brand owners an opportunity to interact with their patient population for consumer education, patient support, and even post-market safety surveillance.
Source: TruTag Technologies
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.